C-reactive protein levels and their relationship with metabolic syndrome and insulin resistance in Mexican adolescents

Journal of Pediatric Endocrinology and Metabolism

Volumn 20, Issue 7, 2007, Pages 797-805

  Cardoso Saldana G ^a   Juarez Rojas J G ^a   Zamora Gonzalez J ^a   Raygoza Perez M ^a   Martinez Alvarado R ^a   Posadas Sanchez R ^a   Posadas Romero, Carlos ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Adolescents; C reactive protein; Insulin resistance; Metabolic syndrome; Obesity

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; TRIACYLGLYCEROL;

ADOLESCENT; ADOLESCENT HEALTH; ARTICLE; BODY MASS; CONTROLLED STUDY; CORONARY RISK; CORRELATION ANALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MEXICO; MULTIPLE REGRESSION; PREVALENCE; PROTEIN BLOOD LEVEL; SCHOOL CHILD; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 34548206610     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2007.20.7.797     Document Type: Article

References (38)

1. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
2. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-369.
3. Ford ES. C-Reactive protein concentration and cardiovascular disease risk factors in children. Findings from the National Health and Nutrition Examination Survey 1999-2000. Circulation 2003; 108: 1053-1058.
4. Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003; 108: 1930-1932.
5. Yasojima K, Schwab C, McGreer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001; 158: 1039-1051.
6. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-2168.
7. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemo-attractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 2531-2534.
8. Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, Koenig W, Schmitz G, Hombach V, Torzewski J. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20: 2094-2099.
9. Chang MK, Binder CJ, Torzewski M, Witztum LJ. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 2002; 99: 13043-13048.
10. Cook DG, Mendall MA, Whincup PH, Carey IM, Ballam L, Morris JE, Miller GJ, Strachan DP. C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. Atherosclerosis 2000; 149: 139-150.
11. Yamamoto KL, Posadas RC, Posadas SR, Zamora GJ, Cardoso SG, Méndez RI. Prevalence and interrelations of cardiovascular risk factors in urban and rural Mexican adolescents. J Adolesc Health 2006; 38: 591-598.
12. Stabouli S, Kotsis V, Papamichael C, Constantopoulos A, Zakopoulos N. Adolescent obesity is associated with high ambulatory blood pressure and increased carotid intimal-medial thickness. J Pediatr 2005; 147: 651-656.
13. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996; 312: 1061-1065.
14. Hanley AJG, Festa A, D'Agostino RB, Wagenknecht LE, Savage PJ, Tracy RP, Sand MF, Haffner SM. Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes 2004; 53: 1773-1781.
15. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111: 1448-1454.
16. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000; 320: 1240-1243.
17. Siedel J, Hägele OE, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983; 29: 1075-1080.
18. Nägele U, Hägele OE, Sauer G, Wiedwemann E, Lehmann P, Wahlefeld AW, Gruber W. Reagent for the enzymatic determination of serum triglycerides with improved lipolytic efficiency. J Clin Chem Biochem 1984; 22: 165-174.
19. +2 precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin Chem 1982; 28: 1379-1388.
20. DeLong DA, DeLong ER, Weed PD. A comparison of methods for the estimation of plasma low and very low density lipoproteins cholesterol. JAMA 1986; 256: 2372-2377.
21. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 1969; 22: 158-161.
22. Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K; American Heart Association. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 2003; 107: 1562-1566.
23. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 2003; 157: 821-827.
24. American Academy of Pediatrics. National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992; 89: 525-584.
25. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003; 26: S33-50.
26. Ledue TB, Weiner DL, Sipe JD, Poulin SE, Collins MF, Rifai N. Analytical evaluation of particle enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 1998; 35: 745-753.
27. Ford ES, Ajani UA, Mokdad AH. The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. Diabetes Care 2005; 28: 878-881.
28. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349: 462-466.
29. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-1818.
30. Wu DM, Chu NF, Shen MH, Chang JB. Plasma C-reactive protein levels and their relationship to anthropometric and lipid characteristics among children. J Clin Epidemiol 2003; 56: 94-100.
31. Moran A, Steffen LM, Jacobs DR Jr, Steinberger J, Pankow JS, Hong CP, Tracy RP, Sinaiko AR. Relation of C-reactive protein to insulin resistance and cardiovascular risk factors in youth. Diabetes Care 2005; 28: 1763-1768.
32. Festa A, D'Agostino R Jr, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, Haffner SM. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord 2001; 25: 1407-1415.
33. Frohlich M. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000; 23: 1835-1839.
34. Bloomgarden ZT. Inflammation, atherosclerosis, and aspects of insulin action. Diabetes Care 2005; 28: 2312-2318.
35. McLaughlin T, Abbasi F, Lamendola C, Liang L, Reaven G, Schaaf P, Reaven P. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 2002; 106: 2908-2912.
36. Baumert J, Doring A, Herder C. Kolb H, Rathmann W, Giani G, Koenig W. Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis 2006; 184: 216-224.
37. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol 1993; 137: 959-965.
38. Howard G, Bergman R, Wagenknecht LE, Haffner SM, Savage PJ, Saad MF, Laws A, D'Agostino RB Jr. Ability of alternative indices of insulin sensitivity to predict cardiovascular risk: comparison with the 'minimal model': Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Ann Epidemiol 1998; 8: 358-369.